Medistim Management
Management criteria checks 2/4
Medistim's CEO is Kari Krogstad, appointed in Sep 2009, has a tenure of 14.92 years. total yearly compensation is NOK7.21M, comprised of 42% salary and 58% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth NOK11.58M. The average tenure of the management team and the board of directors is 9.7 years and 1.6 years respectively.
Key information
Kari Krogstad
Chief executive officer
NOK 7.2m
Total compensation
| CEO salary percentage | 42.0% |
| CEO tenure | 14.9yrs |
| CEO ownership | 0.4% |
| Management average tenure | 9.7yrs |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
Medistim ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 19
Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 04One Medistim ASA (OB:MEDI) Analyst Has Been Cutting Their Forecasts
Nov 10What Does Medistim ASA's (OB:MEDI) Share Price Indicate?
Dec 14Should You Be Adding Medistim (OB:MEDI) To Your Watchlist Today?
Sep 06A Look At The Intrinsic Value Of Medistim ASA (OB:MEDI)
Jun 14Medistim (OB:MEDI) Is Increasing Its Dividend To kr3.75
Apr 21Medistim (OB:MEDI) Is Paying Out A Larger Dividend Than Last Year
Mar 31Statutory Profit Doesn't Reflect How Good Medistim's (OB:MEDI) Earnings Are
Mar 05Medistim's (OB:MEDI) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 01Medistim (OB:MEDI) Is Reinvesting To Multiply In Value
Jan 11Medistim (OB:MEDI) Might Become A Compounding Machine
Sep 29Here's Why I Think Medistim (OB:MEDI) Might Deserve Your Attention Today
Sep 07Here's What Medistim's (OB:MEDI) Strong Returns On Capital Mean
May 17Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?
Mar 19Medistim ASA (OB:MEDI) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 02Here's What You Should Know About Medistim ASA's (OB:MEDI) 1.1% Dividend Yield
Feb 19
A Look Into Medistim's (OB:MEDI) Impressive Returns On Capital
Jan 21Have Insiders Been Selling Medistim ASA (OB:MEDI) Shares?
Dec 27Medistim (OB:MEDI) Has Rewarded Shareholders With An Exceptional 375% Total Return On Their Investment
Dec 10Could The Market Be Wrong About Medistim ASA (OB:MEDI) Given Its Attractive Financial Prospects?
Nov 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | NOK 104m |
| Mar 31 2024 | n/a | n/a | NOK 103m |
| Dec 31 2023 | NOK 7m | NOK 3m | NOK 104m |
| Sep 30 2023 | n/a | n/a | NOK 117m |
| Jun 30 2023 | n/a | n/a | NOK 116m |
| Mar 31 2023 | n/a | n/a | NOK 116m |
| Dec 31 2022 | NOK 9m | NOK 3m | NOK 114m |
| Sep 30 2022 | n/a | n/a | NOK 98m |
| Jun 30 2022 | n/a | n/a | NOK 92m |
| Mar 31 2022 | n/a | n/a | NOK 93m |
| Dec 31 2021 | NOK 6m | NOK 3m | NOK 91m |
| Sep 30 2021 | n/a | n/a | NOK 88m |
| Jun 30 2021 | n/a | n/a | NOK 84m |
| Mar 31 2021 | n/a | n/a | NOK 70m |
| Dec 31 2020 | NOK 6m | NOK 3m | NOK 69m |
| Sep 30 2020 | n/a | n/a | NOK 71m |
| Jun 30 2020 | n/a | n/a | NOK 74m |
| Mar 31 2020 | n/a | n/a | NOK 75m |
| Dec 31 2019 | NOK 4m | NOK 3m | NOK 70m |
| Sep 30 2019 | n/a | n/a | NOK 79m |
| Jun 30 2019 | n/a | n/a | NOK 73m |
| Mar 31 2019 | n/a | n/a | NOK 64m |
| Dec 31 2018 | NOK 4m | NOK 2m | NOK 57m |
| Sep 30 2018 | n/a | n/a | NOK 46m |
| Jun 30 2018 | n/a | n/a | NOK 48m |
| Mar 31 2018 | n/a | n/a | NOK 45m |
| Dec 31 2017 | NOK 4m | NOK 2m | NOK 48m |
Compensation vs Market: Kari's total compensation ($USD683.26K) is above average for companies of similar size in the Norwegian market ($USD466.69K).
Compensation vs Earnings: Kari's compensation has been consistent with company performance over the past year.
CEO
Kari Krogstad (60 yo)
14.9yrs
Tenure
NOK 7,205,702
Compensation
Ms. Kari Eian Krogstad serves as Independent Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & President | 14.9yrs | NOK 7.21m | 0.39% NOK 11.6m | |
| Chief Financial Officer | no data | NOK 2.77m | 0.17% NOK 5.0m | |
| Vice President of Operations | no data | NOK 1.67m | no data | |
| Vice President of Marketing | 14yrs | NOK 1.87m | 0.0087% NOK 261.0k | |
| Chief Innovation Officer | 5.3yrs | NOK 1.91m | 0.043% NOK 1.3m | |
| Chief Business Development Officer | 2.3yrs | NOK 1.68m | 0.032% NOK 962.9k | |
| President of Medistim USA Inc | no data | NOK 3.63m | 0.011% NOK 326.5k | |
| Vice President of Sales - APAC | no data | NOK 2.55m | 0.089% NOK 2.7m | |
| Vice President of Sales EMEA | no data | NOK 1.79m | 0.015% NOK 456.5k | |
| Managing Director of Medistim Norge AS | no data | NOK 1.83m | 0.019% NOK 564.4k |
9.7yrs
Average Tenure
60yo
Average Age
Experienced Management: MEDI's management team is seasoned and experienced (9.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 24.6yrs | NOK 495.00k | 7.02% NOK 210.7m | |
| Independent Director | 1.3yrs | no data | no data | |
| Independent Director | 1.6yrs | no data | no data | |
| Independent Director | 1.3yrs | no data | no data | |
| Independent Director | 10.6yrs | NOK 300.00k | no data | |
| Director | no data | no data | no data | |
| Director | no data | no data | no data |
1.6yrs
Average Tenure
54yo
Average Age
Experienced Board: MEDI's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.